• Explore /
  • Poster
  • / Phase 3 trial of lorlatinib in treatment-naive patients (Pts) with <em>ALK</em>-positive advanced non–small cell lung cancer (NSCLC): Comprehensive plasma and tumor genomic analyses.

Phase 3 trial of lorlatinib in treatment-naive patients (Pts) with ALK-positive advanced non–small cell lung cancer (NSCLC): Comprehensive plasma and tumor genomic analyses.

Abstract Video & Slides Poster

Authors

null

Alessandra Bearz

CRO Centro di Riferimento Oncologico di Aviano, Aviano, Italy

Alessandra Bearz , Jean-Francois Martini , Jacek Jassem , Sang-We Kim , Gee-Chen Chang , Alice Tsang Shaw , Deborah Shepard , Elisa Dall’O , Anna Polli , Holger C. Thurm , Gerard Zalcman , Rosario Garcia Campelo , Konstantin Penkov , Hidetoshi Hayashi , Benjamin J. Solomon

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT03052608

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 9070)

DOI

10.1200/JCO.2022.40.16_suppl.9070

Abstract #

9070

Poster Bd #

57

Abstract Disclosures

Similar Posters

First Author: Laura Mezquita

First Author: Todd Michael Bauer

First Author: Benjamin J. Solomon

First Author: Minsuk Kwon